4HY0

Crystal structure of XIAP BIR3 with T3256336


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.84 Å
  • R-Value Free: 0.262 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.211 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Design and Synthesis of Potent Inhibitor of Apoptosis (IAP) Proteins Antagonists Bearing an Octahydropyrrolo[1,2-a]pyrazine Scaffold as a Novel Proline Mimetic.

Hashimoto, K.Saito, B.Miyamoto, N.Oguro, Y.Tomita, D.Shiokawa, Z.Asano, M.Kakei, H.Taya, N.Kawasaki, M.Sumi, H.Yabuki, M.Iwai, K.Yoshida, S.Yoshimatsu, M.Aoyama, K.Kosugi, Y.Kojima, T.Morishita, N.Dougan, D.R.Snell, G.P.Imamura, S.Ishikawa, T.

(2013) J Med Chem 56: 1228-1246

  • DOI: 10.1021/jm301674z
  • Primary Citation of Related Structures:  
    4HY5, 4HY0, 4HY4

  • PubMed Abstract: 
  • To develop novel inhibitor of apoptosis (IAP) proteins antagonists, we designed a bicyclic octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline bioisostere. This design was based on the X-ray co-crystal structure of four N-terminal amino acid residues (AVPI) of the second mitochondria-derived activator of caspase (Smac) with the X-chromosome-linked IAP (XIAP) protein ...

    To develop novel inhibitor of apoptosis (IAP) proteins antagonists, we designed a bicyclic octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline bioisostere. This design was based on the X-ray co-crystal structure of four N-terminal amino acid residues (AVPI) of the second mitochondria-derived activator of caspase (Smac) with the X-chromosome-linked IAP (XIAP) protein. Lead optimization of this scaffold to improve oral absorption yielded compound 45, which showed potent cellular IAP1 (cIAP1 IC(50): 1.3 nM) and XIAP (IC(50): 200 nM) inhibitory activity, in addition to potent tumor growth inhibitory activity (GI(50): 1.8 nM) in MDA-MB-231 breast cancer cells. X-ray crystallographic analysis of compound 45 bound to XIAP and to cIAP1 was achieved, revealing the various key interactions that contribute to the higher cIAPI affinity of compound 45 over XIAP. Because of its potent IAP inhibitory activities, compound 45 (T-3256336) caused tumor regression in a MDA-MB-231 tumor xenograft model (T/C: -53% at 30 mg/kg).


    Organizational Affiliation

    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
E3 ubiquitin-protein ligase XIAPA, B, C, D, E, F, G, H125Homo sapiensMutation(s): 0 
Gene Names: API3BIRC4IAP3XIAP
EC: 6.3.2 (PDB Primary Data), 2.3.2.27 (UniProt)
Find proteins for P98170 (Homo sapiens)
Explore P98170 
Go to UniProtKB:  P98170
NIH Common Fund Data Resources
PHAROS:  P98170
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1AQ
Query on 1AQ

Download Ideal Coordinates CCD File 
BA [auth G], DA [auth H], K [auth A], N [auth B], P [auth C], S [auth D], V [auth E], Y [auth F](3S,7R,8aR)-2-{(2S)-2-(4,4-difluorocyclohexyl)-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-7-ethoxyoctahydropyrrolo[1,2-a]pyrazine-3-carboxamide
C31 H45 F2 N5 O5
WQLHYSFOEZZZDD-QAPMSZJWSA-N
 Ligand Interaction
ZN
Query on ZN

Download Ideal Coordinates CCD File 
AA [auth G] , CA [auth H] , I [auth A] , J [auth A] , L [auth B] , M [auth B] , O [auth C] , Q [auth D] , 
AA [auth G],  CA [auth H],  I [auth A],  J [auth A],  L [auth B],  M [auth B],  O [auth C],  Q [auth D],  R [auth D],  T [auth E],  U [auth E],  W [auth F],  X [auth F],  Z [auth G]
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1AQIC50 :  200   nM  PDBBind
1AQIC50:  200   nM  BindingDB
Biologically Interesting Molecules (External Reference) 1 Unique
Entity ID: 3
IDChainsNameType/Class2D Diagram3D Interactions
PRD_001138 (1AQ)
Query on PRD_001138
BA [auth G], DA [auth H], K [auth A], N [auth B], P [auth C], S [auth D], V [auth E], Y [auth F](3S,7R,8AR)-2-{(2S)-2-(4,4-DIFLUOROCYCLOHEXYL)-2-[(N-METHYL-L-ALANYL)AMINO]ACETYL}-N-[(4R)-3,4-DIHYDRO-2H-CHROMEN-4-YL]-7-ETHOXYOCTAHYDROPYRROLO[1,2-A]PYRAZINE-3-CARBOXAMIDEPeptide-like /  Antagonist

--

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.84 Å
  • R-Value Free: 0.262 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.211 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 58.336α = 90
b = 100.84β = 90
c = 184.583γ = 90
Software Package:
Software NamePurpose
ALS-BOSdata collection
PHASERphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2013-01-30
    Type: Initial release
  • Version 1.1: 2013-02-27
    Changes: Database references
  • Version 1.2: 2013-08-07
    Changes: Non-polymer description, Structure summary